time in the low DAS categories. This supports that remission should be the primary T2T goal in RA.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3890

FRI0016 NO RELATIONSHIPS BETWEEN ACPA AND PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS

F. Mechid¹, C. Zehraoui¹, M. Meddad², S. Salah³, M. Benidir³, S. Merad⁴, N. Saidi¹, O. Cheikh¹, N. blidi¹, C. Dahou¹. ¹Rheumatology, Mohamed Lamine Debaghine hospital; ²Periodontology, Mustapha Bacha Hospital; ³Immunology; ⁴Bacteriology, Dely brahim, institut Pasteur, Algiers, Algeria

Background: Proteins citrullination contributes to generate anticitrullinated peptide antibodies (ACPA) in rheumatoid arthritis (RA). Porphyromonas gingivalis (Pg) is one of main germs incriminated in the development of periodontitis (PD), it has an enzyme called peptidyl arginine deiminase which is able to citrullinate the host proteins

Objectives: The aim of this study was to seek for a possible association between ACPA and periodontitis

Methods: We conducted a case-control study of 69 patients with early rheumatoid arthritis (<2 years), naive of biotherapy and 138 age- and sex matched healthy controls. Smokers, diabetics, and subjects who received dental care and those who used antibiotics in the previous 6 months were not included. Demographic data and ACPA were determined. A periodontal examination was performed to all participants. Subgingival plaque samples were analysed to seek for Porphyromonas gingivalis (Pg) in both population in the case of periodontitis.

Results: The mean age of our patients was 40.75±12.04, the mean duration of the illness was 14.30±6.76 months (extremes: 1–24 months). ACPA was detected in 88% of patients and the mean titre was 255.57±409.78. PD frequency was higher in patient with PR compared with healthy controls (43% versus 29%) and a significant association was found between PR and PD (p<10⁻³). Patients with RA had 2.46 (CI 1.12 to 5.39) higher odds of having PD compared with healthy controls. In early RA, ACPA titre and rate was not associated with PD (p=0.06, p=0.44 respectively). Regarding the frequency of Porphyromonas gingivalis, there was no significant difference between the PR group and the control group (p=0.45). In addition, there was no significant difference between RA group and controls (p=0.68) concerning Porphyromonas gingivalis and ACPA

Conclusions: Periodontitis is a risk factor for the occurrence of rheumatoid arthritis. The ACPA does not seem to be related to periodontitis. In addition there was no association between ACPA and the presence of porphyromonas gingivalis.

REFERENCES:

- [1] Eriksson K, Nise L, Kats A, Luttrupp E, Catrina AI, Askling J, Jansson L, Alfredsson L, Klareskog L, Lundberg K, Yucel-Lindberg T. Prevalence of Periodontitis in Patients with Established Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. *PLoS One* 2016;11(5):e0155956.
- [2] Laugisch O, Wong A, Sroka A, Kantyka T, Koziel J, Neuhaus K, Sculean A, Venables PJ, Potempa J, Möller B, Eick S. Citrullination in the periodontium - a possible link between periodontitis and rheumatoid arthritis. *Clin Oral Investig* 2016;20(4):675–683.
- [3] Dissick A, Redman RS, Jones M, Rangan BV, Reimold A, Griffiths GR, et al. Association of Periodontitis with Rheumatoid Arthritis: A Pilot Study. *Journal of Periodontology* 2010;81:223–230.
- [4] Mikuls TR, Payne JB, Yu F, et al. Periodontitis and porphyromonas gingivalis in patients with rheumatoid arthritis. *Arthritis & Rheumatology* 2014;66(5):1090–100.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5346

FRI0017 AN EXPLORATORY STUDY ON THE ROLE OF VITAMIN D SUPPLEMENTATION IN IMPROVING PAIN AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

G. Adami¹, O. Viapiana¹, L. Bogliolo², F.P. Cantatore³, M. Varenna⁴, N. Malavolta⁵, A. Del Puente⁶, M. Muratore⁷, G. Orsolini¹, D. Gatti¹, M. Rossini¹, on behalf of Study Group on Osteoporosis and Metabolic Skeletal Diseases of the Italian Society of Rheumatology (SIR). ¹Rheumatology Unit, University of Verona, Verona; ²Rheumatology Unit, Policlinico San Matteo Foundation/University of Pavia, Pavia; ³Rheumatology Unit, University of Foggia, Foggia; ⁴Rheumatology Unit, Gaetano Pini Institute, Milano; ⁵Rheumatology Unit, University of Bologna Sant'Orsola-Malpighi Hospital, Bologna; ⁶Rheumatology Unit, University Federico II of Naples, Napoli; ⁷Rheumatology Unit, Galateo San Cesario Hospital, Lecce, Italy

Background: Lower serum vitamin D levels have been associated with various autoimmune disorders. Especially in patients affected by Rheumatoid Arthritis

(RA), has been observed an inverse correlation between serum levels of 25-hydroxyvitamin D (25OHD), pain and disease activity, but the cause-effect relationship is not clear.

Objectives: The aim of this exploratory study is to investigate the effects of supplementation with cholecalciferol (vitD3) in improving pain and disease activity in RA patients with or without vitamin D deficiency (25OHD<20 ng/ml).

Methods: In this prospective open-label intervention study, patients fulfilling the EULAR/ACR 2010 criteria for diagnosis of RA, in non-remission (DAS28-CRP>2.6), on stable disease-modifying antirheumatic drugs, and whose treatment was not expected to be changed over a 3 month period following inclusion, were recruited. DAS28-CRP, VAS pain and serum levels of 25OHD, were evaluated at the baseline and after 3 months of supplementation with oral 100,000 IU/monthly of vitD3.

Results: A sample composed by 61 patients (47 females), with an average age (SD) of 58.12 years within 26–86 years range were included. At baseline the mean (SD) 25OHD levels were 22.10 ng/mL. 57% of the patients were found to have vitamin D deficiency (<20 ng/mL). Mean serum 25OHD levels improved from 13±5 to 32±12 and from 29±7 to 41±10 ng/mL in patients with or without vitamin D deficiency, respectively. At baseline, mean VAS pain was significantly higher in patients with vitamin D deficiency. In the figure are shown DAS28-CRP and VAS pain at baseline and after 3 months of vitD3 supplementation both in patients with or without vitamin D deficiency. After large doses of VitD3, VAS pain significantly decreased in patients with vitamin D deficiency, while DAS28-CRP significantly improved only in patients without vitamin D deficiency at baseline.

Conclusions: VitD3 supplementation appears to be associated with significant and different effects on pain and disease activity in RA patients dependent on 25OHD serum levels. Vitamin D deficiency (<20 ng/mL) seems to be mainly correlated with pain, while higher levels of 25OHD might have immunomodulatory effects. A randomised, double-blind, low versus high vitD3 dose, placebo-controlled trial is recommended.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5235

FRI0018 THE ABILITY OF DISEASE ACTIVITY MEASURES TO PREDICT MAJOR THERAPEUTIC CHANGE IN US VETERANS WITH RHEUMATOID ARTHRITIS

G. Cannon¹, C.-C. Teng¹, N.A. Accortt², D.H. Collier², T.-C. Lin², B.C. Sauer¹. ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City; ²Amgen, Thousand Oaks, USA

Background: Current rheumatoid arthritis (RA) treatment guidelines recommend the use of disease activity measures (DAMs) to guide RA therapy. These guidelines recommend considering escalation of therapy in RA patients with high or moderate disease activity. Recent work by our group has demonstrated that many RA patients with high/moderate RA by Disease Activity Score with 28 joints (DAS28) did not have therapy escalated despite active disease (DAS28 ≥ 3.2).

Objectives: 1) To determine if the rate of major therapeutic change (MTC) for RA patients with high/moderate disease activity based on DAS28 was similar when measured using two other common DAMs; 2) to compare the ability of different DAMs to predict MTC across the full spectrum of RA disease activity.

Methods: US Veterans enrolled in the VA Rheumatoid Arthritis (VARA) registry with 1) a complete set of DAMs (DAS28, Clinical Disease Activity Index [CDAI], Routine Assessment of Patient Index Data 3 [RAPID3]) recorded (index date), 2) two other visits during the preceding 18 months separated by at least 60 days, and 3) clinical data available for 18 months prior to through 30 days following index date were eligible. Each patient was assessed for MTC within 1 week before and 30 days after index date. MTC was defined as any of the following: 1) initiation of new biologic or nonbiologic DMARD, 2) escalation of DMARD dose by ≥25%, 3) initiation of prednisone (as new agent or after 90 day gap during baseline), or 4) increase in monthly average prednisone dose by 25% and/or 5) injection of 2 or more joints with corticosteroids. MTC was analysed by DAM severity thresholds of 1) high, moderate, low, and remission, and 2) high, high/moderate, and high/moderate/low levels. Analyses of the latter thresholds included sensitivity, specificity, predictive values, and accuracy estimations for MTC at each DAM level.

Results: Of 1776 eligible patients, 89% were male, mean age was 63.4 years, mean disease duration was 13.4 years, 79% tested positive for rheumatoid factor,